跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Anti-EGFRvIII-CAR
首页
药物
Anti-EGFRvIII-CAR
Anti-EGFRvIII-CAR
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Anti-EGFRvIII monoclonal antibody, CAR-T cell and application thereof
申请人: GUANGZHOU FANEN BIOTECHNOLOGY CO LTD
优先权: 2023
CN
CAR-NK cell for treating glioma as well as application and composition of CAR-NK cell
申请人: FIRST TEACHING HOSPITAL XINJIANG MEDICAL UNIV
优先权: 2025
CN
TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRVIII CHIMERIC ANTIGEN RECEPTOR
申请人: UNIV PENNSYLVANIA
优先权: 2013
CN
EP
US
WO
14 件公开
Targeted anti-tumor T cell and preparation method and application thereof
申请人: SHENZHEN BINDE BIOTECHNOLOGY CO LTD
优先权: 2018
CN
CART cell and application thereof in preparation of antitumor drugs
申请人: GUANGZHOU RUIDI BIOTECHNOLOGY CO LTD
优先权: 2026
CN
Double-target chimeric antigen receptor simultaneously targeting EGFRvIII and IL-13R alpha2 and application of double-target chimeric antigen receptor
申请人: UNIV SHANDONG
优先权: 2025
CN
Preparation method for CAR-T cell targeted to EGFRvIII and application
申请人: SUZHOU MAOXING BIOTECHNOLOGY CO LTD
优先权: 2018
CN
VIRAL VECTORS FOR GLIOBLASTOMA CELL THERAPY
申请人: UNIV CALIFORNIA
优先权: 2023
CN
EP
WO
3 件公开
药物
反馈